Aberrant expression of human ortholog of mammalian enabled (hMena) in human colorectal carcinomas: Implications for its role in tumor progression

International Journal of Oncology

Volumn 34, Issue 1, 2009, Pages 53-60

  Toyoda, Akihiro ^a   Kawana, Hidetada ^a   Azuhata, Kouji ^a,b   Yu, Jianyong ^a   Omata, Aya ^a,c   Kishi, Hirohisa ^a,b   Higashi, Morihiro ^a   Harigaya, Kenichi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NARITA RED CROSS HOSPITAL   (Japan)

^c Asahi Central Hospital   (Japan)

Author keywords

Cell migration; Colorectal carcinoma; Ena VASP; Human ortholog of mammalian enabled; Immunohistochemistry; Invasion; Real time PCR; Tumor budding

Indexed keywords

HUMAN ORTHOLOG OF MAMMALIAN ENABLED PROTEIN; MESSENGER RNA; PARAFFIN; PROTEIN HMENA; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ENAH PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CELL ACTIVITY; CELL MIGRATION; CELL MOTILITY; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE SECTION; TUMOR DIFFERENTIATION; TUMOR GROWTH; ADENOCARCINOMA; ADENOMA; CELL MOTION; COLLOID CARCINOMA; COLON; COLORECTAL TUMOR; COMPARATIVE STUDY; DISEASE COURSE; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; RECTUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADENOMA; AGED; BLOTTING, WESTERN; CELL MOVEMENT; COLON; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; RECTUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 60749130633     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000128     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 58: 43-66, 2007.
2. O'Connell JB, Maggard MA and Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96: 1420-1425, 2004.
3. Sobin LH: TNM: principles, history, and relation to other prognostic factors. Cancer 91: 1589-1592, 2001.
4. Bosman FT: Prognostic value of pathological characteristics of colorectal cancer. Eur J Cancer 31A: 1216-1221, 1995.
5. Zlobec I and Lugli A: Prognostic and predictive factors in colorectal cancer. J Clin Pathol 212: 561-569, 2008.
6. Barozzi C, Ravaioli M, D'Errico A, et al: Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer 94: 647-657, 2002.
7. Lyall MS, Dundas SR, Curran S and Murray GI: Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 12: 1184-1191, 2006.
8. Friedl P and Wolf K: Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3: 362-374, 2003.
9. Wang W, Goswami S, Lapidus K, et al: Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 64: 8585-8594, 2004.
10. Wang W, Goswami S, Sahai E, Wyckoff JB, Segall JE and Condeelis JS: Tumor cells caught in the act of invading: their strategy for enhanced cell motility. Trends Cell Biol 15: 138-145, 2005.
11. Lauffenburger DA and Horwitz AF: Cell migration: a physically integrated molecular process. Cell 84: 359-369, 1996.
12. Yamaguchi H and Condeelis J: Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 1773: 642-652, 2007.
13. Barzik M, Kotova TI, Higgs HN, et al: Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping proteins. J Biol Chem 280: 28653-28662, 2005.
14. Krause M, Dent EW, Bear JE, Loureiro JJ and Gertler FB: Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu Rev Cell Dev Biol 19: 541-564, 2003.
15. Di Modugno F, Bronzi G, Scanlan MJ, et al: Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer 109: 909-918, 2004.
16. Di Modugno F, Mottolese M, Di Benedetto A, et al: The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/-hormonal receptor-negative tumors. Clin Cancer Res 12: 1470-1478, 2006.
17. Liu K, Li L, Nisson PE, Gruber C, Jessee J and Cohen SN: Reversible tumorigenesis induced by deficiency of vasodilator-stimulated phosphoprotein. Mol Cell Biol 19: 3696-3703, 1999.
18. Dertsiz L, Ozbilim G, Kayisli Y, Gokhan GA, Demircan A and Kayisli UA: Differential expression of VASP in normal lung tissue and lung adenocarcinomas. Thorax 60: 576-581, 2005.
19. Hu LD, Zou HF, Zhan SX and Cao KM: EVL (Ena/VASP-like) expression is up-regulated in human breast cancer and its relative expression level is correlated with clinical stages. Oncol Rep 19: 1015-1020, 2008.
20. Monney L, Sabatos CA, Gaglia JL, et al: Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415: 536-541, 2002.
21. Kawana H, Tamaru J, Tanaka T, et al: Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol 153: 505-513, 1998.
22. Kitagawa M, Oyama T, Kawashima T, et al: A human protein with sequence similarity to Drosophila mastermind coordinates the nuclear form of notch and a CSL protein to build a transcriptional activator complex on target promoters. Mol Cell Biol 21: 4337-4346, 2001.
23. Fujita Y, Kitagawa M, Nakamura S, et al: CD44 signaling through focal adhesion kinase and its anti-apoptotic effect. FEBS Lett 528: 101-108, 2002.
24. Ueno H, Murphy J, Jass JR, Mochizuki H and Talbot IC: Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 40: 127-132, 2002.
25. Sobin L and Wittekind C: TNM Classification of malignant tumors. Wiley-Liss, New York, 2002.
26. Kirchner T and Brabletz T: Patterning and nuclear beta-catenin expression in the colonic adenoma-carcinoma sequence. Analogies with embryonic gastrulation. Am J Pathol 157: 1113-1121, 2000.
27. Prall F: Tumour budding in colorectal carcinoma. Histopathology 50: 151-162, 2007.
28. Brabletz T, Jung A, Reu S, et al: Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 98: 10356-10361, 2001.
29. Guan JL: Cell migration: developmental methods and protocols. In: Methods in Molecular Biology. Vol. 294. Humana Press Inc., Tatowa, NJ, 2005.
30. Bear JE, Svitkina TM, Krause M, et al: Antagonism between Ena/VASP proteins and actin filament capping regulates fibroblast motility. Cell 109: 509-521, 2002.
31. Loureiro JJ, Rubinson DA, Bear JE, Baltus GA, Kwiatkowski AV and Gertler FB: Critical roles of phosphorylation and actin binding motifs, but not the central proline-rich region, for Ena/vasodilator-stimulated phosphoprotein (VASP) function during cell migration. Mol Biol Cell 13: 2533-2546, 2002.
32. Machesky LM: Sharks' teeth and dunes. Nature 417: 494-497, 2002.
33. Rao J and Li N: Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets 4: 345-354, 2004.
34. Crucitti F, Sofo L, Doglietto GB, et al: Prognostic factors in colorectal cancer: current status and new trends. J Surg Oncol Suppl 2: 76-82, 1991.
35. Horn A, Dahl O and Morild I: The role of venous and neural invasion on survival in rectal adenocarcinoma. Dis Colon Rectum 33: 598-601, 1990.
36. Ratto C, Sofo L, Ippoliti M, Merico M, Doglietto GB and Crucitti F: Prognostic factors in colorectal cancer. Literature review for clinical application. Dis Colon Rectum 41: 1033-1049, 1998.
37. Nathanson SD, Schultz L, Tilley B and Kambouris A: Carcinomas of the colon and rectum. A comparison of staging classifications. Am Surg 52: 428-433, 1986.
38. Compton C, Fenoglio-Preiser CM, Pettigrew N and Fielding LP: American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88: 1739-1757, 2000.
39. Zlobec I, Lugli A, Baker K, et al: Role of APAF-1: E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J Pathol 212: 260-268, 2007.
40. Ueno H, Mochizuki H, Hashiguchi Y, et al: Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127: 385-394, 2004.
41. Nakamura T, Mitomi H, Kikuchi S, Ohtani Y and Sato K: Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroenterology 52: 1432-1435, 2005.
42. Jass JR, Atkin WS, Cuzick J, et al: The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 41: 59-81, 2002.
43. Hase K, Shatney C, Johnson D, Trollope M and Vierra M: Prognostic value of tumor 'budding' in patients with colorectal cancer. Dis Colon Rectum 36: 627-635, 1993.
44. Prall F, Nizze H and Barten M: Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology 47: 17-24, 2005.